Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Katherine Wilemon

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Journal of the American College of Cardiology|December 7, 2019
Familial Hypercholesterolemia Causes Sudden DeathSamuel S Gidding, Katherine Wilemon, Summeet Chugh
JAMA|November 28, 2023
USPSTF Recommendation on Screening for Lipid Disorders in Children and AdolescentsKatherine Wilemon, Joshua W Knowles, Seth J Baum
Journal of Clinical Lipidology|January 6, 2026
Examining barriers and facilitators to testing lipoprotein(a): Understanding at-risk individual and clinician perspectivesShoshana H Bardach, Skye Chernichky-Karcher, Allison Hawke, et al.
Clinical Cardiology|March 23, 2017
PCSK9 inhibitor access barriers-issues and recommendations: Improving the access process for patients, clinicians and payersSeth J Baum, Peter P Toth, James A Underberg, et al.
American Journal of Preventive Cardiology|October 6, 2021
COVID-19 associated risks of myocardial infarction in persons with familial hypercholesterolemia with or without ASCVDKelly D Myers, Katherine Wilemon, Mary P McGowan, et al.
American Journal of Preventive Cardiology|July 26, 2021
Letter to the Editor in response to "Response to Kovanen PT, et al. Letter to the Editor" for original article COVID-19 increases risk of myocardial infarction in persons with familial hypercholesterolemia with or without ASCVDKelly D Myers, Katherine Wilemon, Mary P McGowan, et al.
Circulation. Cardiovascular Quality and Outcomes|July 24, 2019
Effect of Access to Prescribed PCSK9 Inhibitors on Cardiovascular OutcomesKelly D Myers, Niloofar Farboodi, Mkaya Mwamburi, et al.
Journal of Clinical Lipidology|March 8, 2020
Patient acceptance of genetic testing for familial hypercholesterolemia in the CASCADE FH RegistrySamuel S Gidding, Amanda Sheldon, Cynthia L Neben, et al.
American Heart Journal|December 3, 2014
Reducing the burden of disease and death from familial hypercholesterolemia: a call to actionJoshua W Knowles, Emily C O'Brien, Karen Greendale, et al.
Atherosclerosis|October 2, 2018
Familial hypercholesterolaemia patient support groups and advocacy: A multinational perspectiveJules Payne, Simon Williams, Diana Maxwell, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Journal of the American College of Cardiology|December 7, 2019
Familial Hypercholesterolemia Causes Sudden DeathSamuel S Gidding, Katherine Wilemon, Summeet Chugh
JAMA|November 28, 2023
USPSTF Recommendation on Screening for Lipid Disorders in Children and AdolescentsKatherine Wilemon, Joshua W Knowles, Seth J Baum
Journal of Clinical Lipidology|January 6, 2026
Examining barriers and facilitators to testing lipoprotein(a): Understanding at-risk individual and clinician perspectivesShoshana H Bardach, Skye Chernichky-Karcher, Allison Hawke, et al.
Clinical Cardiology|March 23, 2017
PCSK9 inhibitor access barriers-issues and recommendations: Improving the access process for patients, clinicians and payersSeth J Baum, Peter P Toth, James A Underberg, et al.
American Journal of Preventive Cardiology|October 6, 2021
COVID-19 associated risks of myocardial infarction in persons with familial hypercholesterolemia with or without ASCVDKelly D Myers, Katherine Wilemon, Mary P McGowan, et al.
American Journal of Preventive Cardiology|July 26, 2021
Letter to the Editor in response to "Response to Kovanen PT, et al. Letter to the Editor" for original article COVID-19 increases risk of myocardial infarction in persons with familial hypercholesterolemia with or without ASCVDKelly D Myers, Katherine Wilemon, Mary P McGowan, et al.
Circulation. Cardiovascular Quality and Outcomes|July 24, 2019
Effect of Access to Prescribed PCSK9 Inhibitors on Cardiovascular OutcomesKelly D Myers, Niloofar Farboodi, Mkaya Mwamburi, et al.
Journal of Clinical Lipidology|March 8, 2020
Patient acceptance of genetic testing for familial hypercholesterolemia in the CASCADE FH RegistrySamuel S Gidding, Amanda Sheldon, Cynthia L Neben, et al.
American Heart Journal|December 3, 2014
Reducing the burden of disease and death from familial hypercholesterolemia: a call to actionJoshua W Knowles, Emily C O'Brien, Karen Greendale, et al.
Atherosclerosis|October 2, 2018
Familial hypercholesterolaemia patient support groups and advocacy: A multinational perspectiveJules Payne, Simon Williams, Diana Maxwell, et al.
Pageof 3